Table 1.
Baseline clinical characteristics of patients with complete response at first TACE
| Variables | Overall (N=669) | Response (N=149) | No response (N=520) | P value |
|---|---|---|---|---|
| Age (years)* | 62.5 (54.5-71.9) | 62.5 (54.6-71.9) | 62.5 (54.2-71.8) | 0.811 |
| Gender (male, %) | 489 (73.1) | 105 (70.5) | 384 (73.8) | 0.413 |
| Body weight loss, n (%) | 87 (13.0) | 11 (6.8) | 76 (14.6) | 0.021 |
| Virus/Alcoholic/Cryptogenic, n (%) | 578/46/45 (86.4/6.9/6.7) | 131/12/6 (87.9/8.1/4.0) | 447/34/39 (86.0/6.5/7.5) | 0.284 |
| Anti-viral medication use, n (%) | 225 (38.9) | 55 (42.3) | 170 (37.9) | 0.369 |
| BMI (Kg/m2)* | 25.0 (22.6-27.8) | 25.2 (22.9-28.6) | 24.8 (22.6-27.7) | 0.121 |
| DM, n (%) | 197 (29.7) | 45 (30.2) | 152 (29.2) | 0.819 |
| CTP class A/B, n (%) | 543/126 (81.2/18.8) | 131/18 (87.9/12.1) | 412/108 (79.2/20.8) | 0.017 |
| BCLC stage 0/A/B/C, n (%) | 31/140/206/292 (4.6/20.9/30.8/43.6) | 22/62/18/47 (14.8/41.6/12.1/31.5) | 9/78/188/245 (1.7/15.0/36.2/47.1) | <0.001 |
| Ascites, n (%) | 127 (19.0) | 20 (13.4) | 107 (20.6) | 0.049 |
| NLR* | 1.96 (1.37-2.96) | 1.90 (1.33-2.86) | 1.95 (1.41-3.12) | 0.136 |
| PT (INR)* | 1.2 (1.1-1.3) | 1.2 (1.1-1.3) | 1.2 (1.1-1.3) | 0.061 |
| Total bilirubin (mg/dL)* | 0.8 (0.5-1.2) | 0.8 (0.5-1.1) | 0.8 (0.5-1.2) | 0.591 |
| AST (U/L)* | 52 (37-81) | 48 (33-69) | 55 (39-83) | 0.028 |
| ALT (U/L)* | 39 (26-64) | 37 (25-58) | 43 (26-66) | 0.290 |
| Albumin (g/dL)* | 3.59 (3.19-3.93) | 3.68 (3.27-4.00) | 3.56 (3.18-3.92) | 0.464 |
| AFP (ng/mL)* | 41 (10-546) | 18 (7-171) | 46 (10-682) | <0.001 |
| Platelet (1000/μL)* | 112 (77-180) | 94 (65-144) | 125 (81-192) | <0.001 |
| Creatinine (mg/dL)* | 0.79 (0.66-0.96) | 0.73 (0.59-0.92) | 0.75 (0.61-0.95) | 0.545 |
| Sodium (mEq/L)* | 140 (138-142) | 141 (138-142) | 140 (137-142) | 0.031 |
| Tumor numbers, n (%) 1/2&3/>3 | 228/228/213 (34.1/34.1/31.8) | 94/42/13 (63.1/28.2/8.7) | 134/186/200 (25.8/35.8/38.5) | <0.001 |
| Target lesion size (cm)* | 3.5 (2.0-6.2) | 2.4 (1.6-3.5) | 4.1 (2.4-7.4) | <0.001 |
| Within up-to-seven criteria, n (%) | 370 (55.3) | 136 (91.3) | 234 (45.0) | <0.001 |
| Tumor extent unilobar, n (%) | 388 (58.0) | 122 (81.9) | 266 (51.2) | <0.001 |
| Macrovascular invasion, n (%) | 107 (16.0) | 10 (6.7) | 97 (18.7) | <0.001 |
| Fever, n (%) | 205 (30.6) | 30 (20.1) | 175 (33.7) | 0.002 |
| Mortality, n (%) | 397 (59.3) | 48 (32.2) | 349 (67.1) | <0.001 |
| Follow-up time (months)* | 26.6 (14.8-38.9) | 35.8 (26.1-44.9) | 24.0 (11.7-38.1) | <0.001 |
*
Demonstrated as median (IQR).
Abbreviations: AFP, alpha-fetoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BCLC, Barcelona Clinic Liver Cancer; BMI, body mass index; CTP, Child-Turcotte-Pugh; DM, Diabetes mellitus; INR, international normalized ratio; NLR, neutrophil-lymphocyte ratio; TACE, transarterial chemoembolization.